Preliminary report of a phase I/II trial to assess safety and tolerability of an oral Aurora kinase A inhibitor, MLN 8237 (alisertib), in combination with erlotinib in patients with recurrent or metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Borghaei, Hossein [1 ]
Mehra, Ranee [1 ]
Litwin, Samuel [1 ]
Astsaturov, Igor [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-170
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB170
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC).
    Lynch, TJ
    Lilenbaum, R
    Bonomi, P
    Ansari, R
    Govindan, R
    Janne, PA
    Hanna, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 637S - 637S
  • [22] Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC):: A phase I/II trial.
    Sanchez, J. M.
    Mellemgaard, A.
    Perry, M.
    Zatloukal, P.
    Hamm, J.
    Belani, C. P.
    Kim, E.
    Felip, E.
    Berton, M.
    Johri, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 390S - 390S
  • [23] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC)
    Hanna, N
    Bonomi, P
    Lynch, T
    Ansari, R
    Govindan, R
    Janne, R
    Lilenbaum, R
    LUNG CANCER, 2005, 49 : S38 - S38
  • [24] A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC)
    Gold, Kathryn A.
    Byers, Lauren Averett
    Fan, You Hong
    Fujimoto, Junya
    Tse, Warner H.
    Lee, J. Jack
    Gupta, Sanjay
    Wistuba, Ignacio Ivan
    Stewart, David J.
    Gibbons, Don Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Safety of erlotinib in patients with metastatic non-small cell lung cancer (NSCLC) exposed to radiation therapy (RTX)
    Scheffler, M.
    Semrau, R.
    Zander, T.
    Nogova, L.
    Papachristou, I.
    Bos, M.
    Stoelben, E.
    Engel-Riedel, W.
    Wolf, J.
    ONKOLOGIE, 2011, 34 : 153 - 154
  • [26] A pilot trial of erlotinib in combination with stereotactic body radiation therapy (SBRT) for patients with recurrent non-small cell lung cancer (NSCLC)
    Kavanagh, Brian D.
    Abdulrahman, Ramzi
    Camidge, D. R.
    Gerber, David E.
    Bunn, Paul A.
    Schiller, Joan
    Choy, Hak
    Gaspar, Laurie E.
    Wu, Jean
    King, Tracy
    Timmerman, Robert D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S590 - S590
  • [27] PHARMACOKINETIC (PK) EVALUATION OF ERLOTINIB WITH OR WITHOUT SUNITINIB TO TREAT METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN A PHASE II TRIAL
    Ruiz-Garcia, A.
    Khosravan, R.
    Juhasz, E.
    Ciuleanu, T.
    Melnyk, O.
    Mark, Z.
    Boutros, T.
    Tye, L.
    Chao, R.
    Blumenschein, G., Jr.
    ANNALS OF ONCOLOGY, 2010, 21 : 140 - 141
  • [28] Sunitinib in Combination With Erlotinib for the Treatment of Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC): a Phase III Study
    Govindan, R.
    Krzakowski, M. J.
    Szczesna, A.
    Strausz, J.
    Makhson, A. N.
    Reck, M.
    Tye, L.
    Zhang, K.
    Chao, R. C.
    Scagliotti, G. V.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S557 - S557
  • [29] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Okano, Yoshio
    Shinohara, Tsutomu
    Machida, Hisanori
    Hatakeyama, Nobuo
    Takeuchi, Eiji
    Doi, Hiroyuki
    Kubota, Tetsuya
    Yokoyama, Akihito
    Ogushi, Fumitaka
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
  • [30] TG01, a new potent COX-2 inhibitor in combination with erlotinib in metastatic or recurrent non-small cell lung cancer (NSCLC) patients: A phase 1 study
    Reckamp, K. L.
    Patel, R.
    Chen, L.
    Gitlitz, B. J.
    Davies, A. M.
    Jezior, D.
    Zaknoen, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345